Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
- 8 Japan Drug Majors’ Combined Sales Rise 10.2% in FY2021 on Global Brands, Strong Offshore Presence Is Key to Further Growth
May 17, 2022
- Minomycin Stockout Looms in Mid-June over Manufacturing Delays: Pfizer
May 17, 2022
- Shionogi Grabs Europe and Asia Rights to F2G’s Antifungal Drug
May 17, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
May 16, 2022
- Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
- Otsuka Ends Vadadustat Global License Deal with Akebia
May 16, 2022
- Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
- Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
May 16, 2022
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Mitsubishi Tanabe Incurs Operating Loss for 3 Years Running, Logs Write-Down on OA Drug
May 16, 2022
- Eisai Seeks to File Lecanemab in Japan, US, Europe in FY2022: CEO
May 16, 2022
- Seikagaku’s Dry Eye Drug Enters PIII in US
May 16, 2022
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Nichi-Iko Files for Debt Reorganization, Incurs Loss of Over 100 Billion Yen
May 13, 2022
- Taiho Buys Back Rights to EGFR-TKI, Inks Collab with Cullinan Oncology
May 13, 2022
- Opdivo Tops Japan Sales Ranking for 4 Months on End in April: Encise
May 13, 2022
- Japan Ethical Drug Sales Up 0.4% in March: Crecon
May 13, 2022
- Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
May 12, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…